Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces AdvanceBio Peptide Mapping Columns

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
New HPLC and HILIC solutions enable faster, more robust analysis in biopharmaceutical discovery.

Agilent Technologies Inc. has introduced the latest updates to its AdvanceBio family of columns.

The new AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns are designed to deliver exceptional performance for the separation, characterization and analysis of a wide range of proteins, monoclonal antibodies, peptides and additional biologics.

Each of these columns enables users to achieve the highest-resolution results, faster than ever before.

“We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed,” said Anne Jones, Agilent’s vice president and general manager for the chemistries business.

Jones continued, “These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography.”

The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity.

In fact, it can produce exceptional analytical results two to three times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes.

Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps.

All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.

Applications

The AdvanceBio Peptide Mapping column is excellent for highly complex peptide mapping and will provide 100 percent sequence coverage of many protein digests, including rhEPO with 45 glycopeptide matches.

These features are explored in the application note, High-Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column.

The ZORBAX RRHD 300-HILIC columns are the only sub 2-μm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities and biopharmaceuticals.

Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns.

For 1.8 μm particles, the ZORBAX RRHD 300-HILIC columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC.

These features are explored in the application note, Analysis of Erythropoietin Glycopeptides and Glycoforms by HILIC and RP Chromatography.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Announces Agreement with Picometrics Technologies
Agilent to provide Picometrics' biopharmaceutical customers with combined solutions for capillary electrophoresis (CE), laser induced fluorescence (LIF) detection and mass spectrometry.
Friday, January 17, 2014
Agilent, University of Rouen and A*STAR’s Bioprocessing Technology Institute to Collaborate
The collaborations aims to further innovation in biopharmaceuticals and glycomics through developing tools to effectively analyze biologics and vaccines.
Thursday, May 23, 2013
Agilent Technologies, University of Rouen and A*STAR’s Bioprocessing Technology Institute Collaborate
Organisations will work together to further innovation in biopharmaceuticals and glycomics.
Thursday, May 23, 2013
Agilent Technologies Introduces Verified Dissolution Components for Pharmaceutical Market
Agilent Technologies Inc. introduced a new series of verified dissolution components, including molded vessels as well as paddle and basket shafts.
Wednesday, May 15, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Merck-Serono Adopts Agilent Technologies’ Electronic Lab Notebook for Biology Research
Agilent Technologies Inc. have announced that Merck-Serono, a division of Merck KGaA, Darmstadt, Germany, has selected the Agilent OpenLAB Electronic Lab Notebook (ELN) to enhance scientific collaboration globally throughout R&D for finding new small molecules and biopharmaceuticals.
Tuesday, November 23, 2010
Scientific News
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
Study Reveals New Method to Develop More Efficient Drugs
A new study suggests a new approach to develop highly-potent drugs which could overcome current shortcomings of low drug efficacy and multi-drug resistance in the treatment of cancer as well as viral and bacterial infections.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!